Adverse effects of drugs and medicaments, subsequent encounter

Code Families in This Category

• T43 Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified · 19
• T50 Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances · 19
• T45 Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified · 15
• T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified · 13
• T40 Poisoning by, adverse effect of and underdosing of narcotics and psychodysleptics [hallucinogens] · 13
• T36 Poisoning by, adverse effect of and underdosing of systemic antibiotics · 11
• T44 Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system · 11
• T46 Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system · 11
• T47 Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system · 10
• T48 Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system · 10
• T49 Poisoning by, adverse effect of and underdosing of topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinorlaryngological and dental drugs · 10
• T39 Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics · 9
• T42 Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs · 9
• T37 Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics · 8
• T41 Poisoning by, adverse effect of and underdosing of anesthetics and therapeutic gases · 7

ICD-10-CM Codes in This Category (first 100 of 175)

• T36.0X5D — Adverse effect of penicillins, subsequent encounter
• T36.1X5D — Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter
• T36.2X5D — Adverse effect of chloramphenicol group, subsequent encounter
• T36.3X5D — Adverse effect of macrolides, subsequent encounter
• T36.4X5D — Adverse effect of tetracyclines, subsequent encounter
• T36.5X5D — Adverse effect of aminoglycosides, subsequent encounter
• T36.6X5D — Adverse effect of rifampicins, subsequent encounter
• T36.7X5D — Adverse effect of antifungal antibiotics, systemically used, subsequent encounter
• T36.8X5D — Adverse effect of other systemic antibiotics, subsequent encounter
• T36.95XD — Adverse effect of unspecified systemic antibiotic, subsequent encounter
• T36.AX5D — Adverse effect of fluoroquinolone antibiotics, subsequent encounter
• T37.0X5D — Adverse effect of sulfonamides, subsequent encounter
• T37.1X5D — Adverse effect of antimycobacterial drugs, subsequent encounter
• T37.2X5D — Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter
• T37.3X5D — Adverse effect of other antiprotozoal drugs, subsequent encounter
• T37.4X5D — Adverse effect of anthelminthics, subsequent encounter
• T37.5X5D — Adverse effect of antiviral drugs, subsequent encounter
• T37.8X5D — Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter
• T37.95XD — Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter
• T38.0X5D — Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter
• T38.1X5D — Adverse effect of thyroid hormones and substitutes, subsequent encounter
• T38.2X5D — Adverse effect of antithyroid drugs, subsequent encounter
• T38.3X5D — Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter
• T38.4X5D — Adverse effect of oral contraceptives, subsequent encounter
• T38.5X5D — Adverse effect of other estrogens and progestogens, subsequent encounter
• T38.6X5D — Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter
• T38.7X5D — Adverse effect of androgens and anabolic congeners, subsequent encounter
• T38.805D — Adverse effect of unspecified hormones and synthetic substitutes, subsequent encounter
• T38.815D — Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter
• T38.895D — Adverse effect of other hormones and synthetic substitutes, subsequent encounter
• T38.905D — Adverse effect of unspecified hormone antagonists, subsequent encounter
• T38.995D — Adverse effect of other hormone antagonists, subsequent encounter
• T39.015D — Adverse effect of aspirin, subsequent encounter
• T39.095D — Adverse effect of salicylates, subsequent encounter
• T39.1X5D — Adverse effect of 4-Aminophenol derivatives, subsequent encounter
• T39.2X5D — Adverse effect of pyrazolone derivatives, subsequent encounter
• T39.315D — Adverse effect of propionic acid derivatives, subsequent encounter
• T39.395D — Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
• T39.4X5D — Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter
• T39.8X5D — Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter
• T39.95XD — Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter
• T40.0X5D — Adverse effect of opium, subsequent encounter
• T40.2X5D — Adverse effect of other opioids, subsequent encounter
• T40.3X5D — Adverse effect of methadone, subsequent encounter
• T40.415D — Adverse effect of fentanyl or fentanyl analogs, subsequent encounter
• T40.425D — Adverse effect of tramadol, subsequent encounter
• T40.495D — Adverse effect of other synthetic narcotics, subsequent encounter
• T40.5X5D — Adverse effect of cocaine, subsequent encounter
• T40.605D — Adverse effect of unspecified narcotics, subsequent encounter
• T40.695D — Adverse effect of other narcotics, subsequent encounter
• T40.715D — Adverse effect of cannabis, subsequent encounter
• T40.725D — Adverse effect of synthetic cannabinoids, subsequent encounter
• T40.905D — Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter
• T40.995D — Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter
• T41.0X5D — Adverse effect of inhaled anesthetics, subsequent encounter
• T41.1X5D — Adverse effect of intravenous anesthetics, subsequent encounter
• T41.205D — Adverse effect of unspecified general anesthetics, subsequent encounter
• T41.295D — Adverse effect of other general anesthetics, subsequent encounter
• T41.3X5D — Adverse effect of local anesthetics, subsequent encounter
• T41.45XD — Adverse effect of unspecified anesthetic, subsequent encounter
• T41.5X5D — Adverse effect of therapeutic gases, subsequent encounter
• T42.0X5D — Adverse effect of hydantoin derivatives, subsequent encounter
• T42.1X5D — Adverse effect of iminostilbenes, subsequent encounter
• T42.2X5D — Adverse effect of succinimides and oxazolidinediones, subsequent encounter
• T42.3X5D — Adverse effect of barbiturates, subsequent encounter
• T42.4X5D — Adverse effect of benzodiazepines, subsequent encounter
• T42.5X5D — Adverse effect of mixed antiepileptics, subsequent encounter
• T42.6X5D — Adverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
• T42.75XD — Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
• T42.8X5D — Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter
• T43.015D — Adverse effect of tricyclic antidepressants, subsequent encounter
• T43.025D — Adverse effect of tetracyclic antidepressants, subsequent encounter
• T43.1X5D — Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
• T43.205D — Adverse effect of unspecified antidepressants, subsequent encounter
• T43.215D — Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
• T43.225D — Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter
• T43.295D — Adverse effect of other antidepressants, subsequent encounter
• T43.3X5D — Adverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
• T43.4X5D — Adverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
• T43.505D — Adverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter
• T43.595D — Adverse effect of other antipsychotics and neuroleptics, subsequent encounter
• T43.605D — Adverse effect of unspecified psychostimulants, subsequent encounter
• T43.615D — Adverse effect of caffeine, subsequent encounter
• T43.625D — Adverse effect of amphetamines, subsequent encounter
• T43.635D — Adverse effect of methylphenidate, subsequent encounter
• T43.655D — Adverse effect of methamphetamines, subsequent encounter
• T43.695D — Adverse effect of other psychostimulants, subsequent encounter
• T43.8X5D — Adverse effect of other psychotropic drugs, subsequent encounter
• T43.95XD — Adverse effect of unspecified psychotropic drug, subsequent encounter
• T44.0X5D — Adverse effect of anticholinesterase agents, subsequent encounter
• T44.1X5D — Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter
• T44.2X5D — Adverse effect of ganglionic blocking drugs, subsequent encounter
• T44.3X5D — Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
• T44.4X5D — Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
• T44.5X5D — Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
• T44.6X5D — Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
• T44.7X5D — Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
• T44.8X5D — Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
• T44.905D — Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
• T44.995D — Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter

The remaining 75 codes are reachable through the code families above.